Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-01-10
1995-04-04
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514188, 514272, 514331, 514362, 514370, 514400, 514471, 424653, A61K 31415, A61K 31345, A61K 3324
Patent
active
054038308
ABSTRACT:
The present invention relates to pharmaceutical compositions useful for treating or preventing gastrointestinal disorders. These compositions comprise a bismuth-containing agent, preferably a campylobacter-inhibiting bismuth-containing agent such as bismuth subsalicylate and bismuth subcitrate, and a histamine-2 receptor blocking anti-secretory agent such as cimetidine.
The present invention further relates to methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering a bismuth-containing agent and a histamine-2 receptor blocking anti-secretory agent.
REFERENCES:
patent: 4148912 (1979-04-01), Vincent et al.
patent: 4959384 (1990-09-01), Kraft et al.
patent: 5008256 (1991-04-01), Clitherow
Ward et al., "A Double Blind Trial of the Treatment of Gastric Ulcers with a Combination of DeNol and Cimetidine", Adelaide Scientific Meeting, 1979, Programme Abstracts of Papers, Australian Mineral Foundation, Oct. 8-9; p. A30.
Deutsche Med. Wochenschrift, vol. 112, No. 37, Sep. 1987, pp. 1407-1411.
Wiener Klinische Wochenschrift, vol. 99, No. 14, 17 Jul. 1987, pp. 493-497.
Chemical Abstracts, vol. 107, No. 5, 34d Aug. 1987, p. 397, Abstract No. 36471w.
Goldenberg et al., "Protective Effect of Pepto-Bismol Liquid on the Gastric Mucosa of Rats", Gastroenterology, 69(3), pp. 636-640 (1975).
Vantrappen et al., "Randomized Open Controlled Trial of Colloidal Bismuth Subcitrate Tablets and Cimetidine in the Treatment of Duodenal Ulcers", Gut, 21(4), pp. 329-333 (1980).
Wieriks et al., "Pharmacological Properties of Colloidal Bismuth Subcitrate (CBS, DE-NOL.sup.R)", Scand. J. Gastroenterol., 17, Supplement 80, pp. 11-16 (1982).
Koo et al., "Selective Coating of Gastric Ulcer by Tripotassium Dicitrato Bismuthate in the Rat", Gastroenterology, 82, pp. 864-870 (1982).
Lu et al., "Effect of Furaxon and its Analogs on Gastrointestinal Propulsion in Mice", Beijing Yixueyuan Xuebao, 15, pp. 185-187 (1983).
Marshall et al., "Unidentified Curved Bacilli in the Stomach of Patients with Gastritis and Peptic Ulceration", Lancet, 1, pp. 1311-1315 (Jun. 16, 1984).
McLean et al., "Microbes, Peptic Ulcer and Relapse Rates with Different Drugs", Lancet, 2, pp. 525-526 (Sep. 1, 1984).
Hislop et al., "Histological Improvement of Active Chronic Gastritis in Patients Treated with De-Nol", Australia and New Zealand Journal of Medicine, 14, p. 907 (1984).
Lam et al., "Randomised Crossover Trial of Tripotassium Dicitrato Bismuthate Versus High Dose Cimetidine for Duodenal Ulcers Resistant to Standard Dose of Cimetidine", Gut, 25, pp. 703-706 (1984).
Zeng Zhi-Tian et al., "Double-Blind Short-Term Trial of Furazolidone in Peptic Ulcer", Lancet, 1, pp. 1048-1049 (May 4, 1985).
Piper, "Bacteria, Gastritis, Acid Hyposecretion and Peptic Ulcer", The Medical Journal of Australia, 142, p. 431 (1985).
Pinkard et al., "Campylobacter-Like Organisms From the Human Stomach-Detection, Characterization, and in Vitro Susceptibilities", Campylobacter III (Pearson et al., editors; 1985), 171-172.
Goodwin et al., "The Association of Campylobacter Pyloridis with Gastritis, and Its In Vitro Sensitivity to Antibiotics and Anti-Ulcer Agents", Australia and New Zealand Journal of Medicine, 15 (1 Supplement 1), p. 153 (1985).
Lambert et al., "Campylobacter-Like Organisms (CLO)--In Vivo and In Vitro Susceptibility to Antimicrobial and Anti-Ulcer Therapy", Gastroenterology, 88, p. 1462 (1985).
McNulty et al., "Successful Therapy of Campylobacter Pyloridis Gastritis", Gastroenterology, 90, p. 1547 (1986).
Goodwin et al., "The Minimum Inhibitory and Bactericidal Concentrations of Antibiotics and Anti-Ulcer Agents Against Campylobacter Pyloridis", Journal of Antimicrobial Chemotherapy, 17, pp. 309-314 (1986).
Hirschl et al., "Sensitivity of Campylobacter Pyloridis to Antimicrobials and Anti-Ulcer Drugs", Z. Antimikrob Antineoplast. Chemother., 4 (2), pp. 45-49 (1986).
Salmon, "Combination Treatment: Colloidal Bismuth Subcitrate with H.sub.2 -Antagonist", Digestion, 37, pp. 42-46 (1987).
"Notice of Opposition Against a European Patent", European Patent No. 282,132, by Opponent SmithKline Beecham pic. (Jun. 28, 1993).
"Notice of Opposition", European Patent No. 282,132, by Opponent Glaxo Group Limited, (Jul. 7, 1993).
Peterson et al., Gastroenterology, 1979, 77, 1015-1020.
Martin et al., The Lancet, 1981, 7-10.
Digestion, vol. 37, Supplement 2, Jun. 1987.
Gut, 1984, 25, pp. 697-702.
Pharmac. Ther., 1984, 26, pp. 221-234.
Letter by M. C. Brooks dated 11 Jun. 1991, during examination of European Patent No. 206,626.
Letter by J. L'Helgoualch dated 8 Dec. 1992, during examination of European Patent Application No. 88200396.5, Publication No. 282,131.
Mohl Douglas C.
Rasser Jacobus C.
Raymond Richard L.
The Proctor & Gamble Company
Zerby Kim William
LandOfFree
Compositions and methods of treating gastrointestinal disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of treating gastrointestinal disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of treating gastrointestinal disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2380774